Posts

Showing posts with the label Sturge-Weber syndrome (SWS) market forecast

Sturge-Weber Syndrome (SWS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Sturge-Weber syndrome (SWS) is a neurocutaneous syndrome characterized by angiomas involving the face, choroid, and leptomeninges. Sturge-Weber syndrome (SWS) is caused by mistake (mutation) in the GNAQ gene. This gene makes a protein involved in regulating blood vessels' growth. ·        The exact sturge-weber syndrome (SWS) incidence and prevalence are unknown. One estimate places the incidence at 1 in 20,000-50,000 live births.   Thelansis’s “Sturge-Weber Syndrome (SWS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sturge-Weber Syndrome (SWS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China)...

Sturge-Weber Syndrome (SWS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Sturge-Weber syndrome (SWS) is a neurocutaneous syndrome characterized by angiomas involving the face, choroid, and leptomeninges. Sturge-Weber syndrome (SWS) is caused by mistake (mutation) in the GNAQ gene. This gene makes a protein involved in regulating blood vessels' growth. ·        The exact Sturge-weber syndrome (SWS) incidence and prevalence are unknown. One estimate places the incidence at 1 in 20,000-50,000 live births. Thelansis’s “Sturge-Weber Syndrome (SWS) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sturge-Weber Syndrome (SWS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs...

Sturge-Weber syndrome (SWS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Image
Sturge-Weber syndrome (SWS) is a neurocutaneous syndrome characterized by angiomas involving the face, choroid, and leptomeninges. Etiology- Sturge-Weber syndrome (SWS) is caused by a mistake (mutation) in the GNAQ gene. This gene makes a protein that is involved in regulating the growth of blood vessels. Epidemiology- The exact incidence and prevalence are unknown. One estimate places the incidence at 1 in 20,000-50,000 live births. Approximately 3 in 1,000 babies are born with a port-wine birthmark, but only approximately 6% of individuals with a port-wine birthmark on the face develop the neurological abnormalities associated with SWS. The competitive landscape of Sturge-Weber syndrome (SWS) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Sturge-Weber syndrome (SWS) across 8 MM market from the centre of Excellence/ ...